Evidence map›Paper›PMID 38019656›Full record

ArticleThe Journal of infectious diseases2024

Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.

Andrew H Karaba, William R Morgenlander, Trevor S Johnston, Camille Hage, Andrew Pekosz, Christine M Durand, Dorry L Segev, Mark A Robien, Peter S Heeger, Christian P Larsen and 4 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04969263 (Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04969263 phase2completednot on this map

Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2021 to 2023Enrolled81ConditionsKidney Transplant RecipientsArmsBNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. PhIP-Seq: methods, applications and challenges.Frontiers in bioinformatics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Andrew H KarabaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
William R MorgenlanderInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Trevor S JohnstonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Camille HageDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Andrew PekoszDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3248-1761
Christine M DurandDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Dorry L SegevDepartment of Surgery, NewYork University Grossman School of Medicine, New York, New York, USA.
Mark A RobienTransplantation Branch, Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
Peter S HeegerDepartment of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles California, USA.
Christian P LarsenDepartment of Medicine, Emory University, Atlanta, Georgia, USA.
Joel N BlanksonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
William A WerbelDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
H Benjamin LarmanInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron A R TobianDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-0517-3766
Johns Hopkins University · USCedars-Sinai Medical Center · USEmory University · USNational Institute of Allergy and Infectious Diseases · USNew York University · US

Funding

HOPE in Action: A Clinical Trial of HIV-to-HIV Liver TransplantationU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2018 to 2026
$25.5M
Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
T-cell depletion and maintenance of the HIV-1 latent reservoir in distinct tissue compartmentsR01DK131926 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Melissa Laird Smith, AARON A TOBIAN · 2022 to 2026
$3.6M
Design and Analysis of Displayed PeptidomesR01GM136724 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI LARMAN, HARRY BENJAMIN, RUCZINSKI, INGO · 2020 to 2023
$1.9M
Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2K08AI156021 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARABA, ANDREW HOOVER · 2021 to 2025
$994k
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
NIAID NIH HHS K08 AI156021NIAID NIH HHS K23 AI157893NIAID NIH HHS U01 AI138897NIDDK NIH HHS R01 DK131926NIGMS NIH HHS R01 GM136724NIGMS NIH HHS T32 GM136577NIH HHS U01 AI138897
6 · The paper itself

Abstract

Kidney transplant recipients (KTRs) develop decreased antibody titers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared to healthy controls (HCs), but whether KTRs generate antibodies against key epitopes associated with neutralization is unknown. Plasma from 78 KTRs from a clinical trial of third doses of SARS-CoV-2 vaccines and 12 HCs underwent phage display immunoprecipitation and sequencing (PhIP-Seq) to map antibody responses against SARS-CoV-2. KTRs had lower antibody reactivity to SARS-CoV-2 than HCs, but KTRs and HCs recognized similar epitopes associated with neutralization. Thus, epitope gaps in antibody breadth of KTRs are unlikely responsible for decreased efficacy of SARS-CoV-2 vaccines in this immunosuppressed population. Clinical Trials Registration.  NCT04969263.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesEpitope MappingKidney TransplantationSARS-CoV-2Spike Glycoprotein, CoronavirusTransplant RecipientsAdultAgedAntibodies, NeutralizingCase-Control StudiesEpitopesFemaleHumansMaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopesSpike Glycoprotein, Coronavirusantibodiesimmunocompromised hostsSARS-CoV-2transplantationvaccination

Identifiers

PMID38019656
PMCPMC11095532
OpenAlexW4389131630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.